HC Wainwright Has Bearish Estimate for RenovoRx Q4 Earnings

RenovoRx, Inc. (NASDAQ:RNXT) – Research analysts at HC Wainwright lowered their Q4 2027 EPS estimates for RenovoRx in a report released on Friday, November 6th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.01) per share for the quarter, down from their previous estimate of $0.01. The consensus estimate for RenovoRx’s current full-year earnings is ($0.28) per share.

Several other research firms also recently commented on RNXT. Weiss Ratings raised shares of RenovoRx from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 2nd. Wall Street Zen cut shares of RenovoRx from a “hold” rating to a “sell” rating in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $8.50.

RenovoRx Stock Performance

Shares of RenovoRx stock opened at $1.18 on Monday. RenovoRx has a 52-week low of $0.70 and a 52-week high of $2.59. The stock’s 50-day simple moving average is $1.52 and its 200 day simple moving average is $1.11.

RenovoRx (NASDAQ:RNXT) last released its earnings results on Thursday, November 5th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). RenovoRx had a negative net margin of 469.02% and a negative return on equity of 133.49%. The company had revenue of $1.07 million for the quarter, compared to the consensus estimate of $1.06 million.

Institutional Trading of RenovoRx

An institutional investor recently bought a new stake in RenovoRx stock. T3 Companies LLC bought a new position in RenovoRx, Inc. (NASDAQ:RNXT) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 96,800 shares of the company’s stock, valued at approximately $151,000. T3 Companies LLC owned about 0.21% of RenovoRx at the end of the most recent reporting period. 3.10% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting RenovoRx

Here are the key news stories impacting RenovoRx this week:

• Neutral Sentiment: A short-interest update reported zero shares short and a 0.0-day short-interest ratio. That suggests no reported short position, although the accompanying description of an increase conflicts with the figure. [No article link provided]
• Negative Sentiment: HC Wainwright cut its estimates for RenovoRx’s losses in several coming quarters and fiscal years. Its FY2026 forecast worsened to a $0.29-per-share loss from $0.21, while its FY2027 estimate shifted to a $0.19 loss from $0.04. The firm also reduced its projected profits for FY2029 and FY2030, implying a later path to profitability than previously expected. HC Wainwright Estimates RenovoRx’s Q4 Earnings
• Negative Sentiment: Wall Street Zen lowered its rating on RNXT to “Sell,” adding to the cautious analyst sentiment. RenovoRx Rating Lowered to Sell at Wall Street Zen

RenovoRx Company Profile

RenovoRx, Inc. is a clinical-stage biopharmaceutical company developing targeted treatments for solid tumors. The company’s approach is based on its Trans-Arterial Micro-Perfusion (TAMP) platform, which is designed to deliver chemotherapy directly into tumor tissue through the arterial system while limiting exposure to surrounding healthy tissue. RenovoRx’s lead investigational product, RenovoCath, is a localized drug-delivery system intended to support the administration of anticancer therapies to tumors.